Skip to Main Content

Author Details

Yana Pikman
Dana Farber Cancer Institute
2005
40
17
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
38096371Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.Blood2024
37264747A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors.Cancer Med2023
38028059Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation.Clin Case Rep2023
37648673DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia.Blood Adv2023
37725576Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.Clin Cancer Res2023
37419244Outlier Expression of Isoforms by Targeted or Total RNA Sequencing Identifies Clinically Significant Genomic Variants in Hematolymphoid Tumors.J Mol Diagn2023
37381775<i>ETV6</i> fusions from insertions of exons 3-5 in pediatric hematologic malignancies.Haematologica2023
37369986Impact of cytoreduction and remission status on hematopoietic cell transplantation outcomes in pediatric myelodysplastic syndrome and related disorders.Pediatr Blood Cancer2023
34341479Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.Leukemia2022
35476984Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells.Cell Rep2022
35405016Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts.Cancer Discov2022
35534777IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia.Nat Cancer2022
35090166Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn.Blood Adv2022
34582559The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.Blood2022
34624079SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.Blood2022
33394740Targeting the Ras pathway in pediatric hematologic malignancies.Curr Opin Pediatr2021
33790022Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor.Sci Transl Med2021
33563661Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium.Cancer Discov2021
33506554Corrigendum.Pediatr Blood Cancer2021
33026184Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001.Pediatr Blood Cancer2021
32232478Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma.Blood Adv2020
31771968Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.Cancer Discov2020
32826232The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.Cancer Discov2020
29515000Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.Sci Transl Med2018
30049809Targeted therapy for fusion-driven high-risk acute leukemia.Blood2018
29603593Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.Pediatr Blood Cancer2018
28151717Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.Clin Cancer Res2017
28191887The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.Nat Med2017
27325891Targeting MTHFD2 in acute myeloid leukemia.J Exp Med2016
26292080A Prospective Cohort Quality Improvement Study to Reduce the Time to Antibiotics for New Fever in Neutropenic Pediatric Oncology Inpatients.Pediatr Blood Cancer2016
24525236SYK is a critical regulator of FLT3 in acute myeloid leukemia.Cancer Cell2014
24190688Pulmonary hypertension associated with scurvy and vitamin deficiencies in an autistic child.Pediatrics2013
19287095The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model.J Clin Invest2009
18231579The CDK-activating kinase (CAK) Csk1 is required for normal levels of homologous recombination and resistance to DNA damage in fission yeast.PLoS One2008
18723266Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray.Exp Hematol2008
17906464Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.Curr Opin Oncol2007
16868251MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.Blood2006
16834459MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.PLoS Med2006
16754208Peters anomaly in association with multiple midline anomalies and a familial chromosome 4 inversion.Ophthalmic Genet2006
16365288Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.Proc Natl Acad Sci U S A2005
  • 1 - 40 of 40

Recommended Authors

Vanda Pharmaceuticals Inc.
Career Start Year 2010
Number of shared co-authors 2
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 1
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Oregon Health & Science University
Career Start Year 2008
Number of shared co-authors 2
UT MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 8
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 2
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 3
St Jude Children's Research Hospital
Career Start Year 2006
Number of shared co-authors 9
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Career Start Year 2004
Number of shared co-authors 8
Adelaide Medical School, University of Adelaide
Career Start Year 2003
Number of shared co-authors 6
Emory University School of Medicine
Career Start Year 2003
Number of shared co-authors 2
Clinical Research Division, Fred Hutchinson Cancer Research Center
Career Start Year 2003
Number of shared co-authors 4
Hannover Medical School
Career Start Year 2002
Number of shared co-authors 4
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 1
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 6
Washington University School of Medicine in St. Louis
Career Start Year 1998
Number of shared co-authors 0
Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 4
University Hospital Erlangen
Career Start Year 1998
Number of shared co-authors 2
University of Cambridge
Career Start Year 1996
Number of shared co-authors 18
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 10
Mayo Clinic
Career Start Year 1995
Number of shared co-authors 6
The University of Chicago
Career Start Year 1994
Number of shared co-authors 8
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 8
University of Paris
Career Start Year 1993
Number of shared co-authors 14
Oregon Health and Science University
Career Start Year 1993
Number of shared co-authors 7
Massachusetts General Hospital
Career Start Year 1993
Number of shared co-authors 8
Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf
Career Start Year 1992
Number of shared co-authors 4
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1991
Number of shared co-authors 9
St. Jude Children's Research Hospital
Career Start Year 1988
Number of shared co-authors 3
Fred Hutchinson Cancer Research Centre
Career Start Year 1987
Number of shared co-authors 10

Collaborators

Dana-Farber Cancer Institute
Co-authored papers 18
Dana-Farber Cancer Institute
Co-authored papers 11
Universite de Paris, INSERM, CNRS
Co-authored papers 7
Dana-Farber Cancer Institute
Co-authored papers 6
Universite Paris Cite, INSERM, CNRS
Co-authored papers 5
Dana Farber Cancer Institute
Co-authored papers 5
Universite de Paris, Inserm CIC 1427
Co-authored papers 5
University of Parma
Co-authored papers 4
Boston Children's Hospital
Co-authored papers 4
Duke University School of Medicine Durham
Co-authored papers 4
Co-authored papers 3
The Broad Institute of MIT and Harvard
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
University of Washington
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Universite Cote d'Azur, INSERM U5
Co-authored papers 2
Department of Pharmaceutical Chemistry, University of California san francisco
Co-authored papers 2
Merck & Co.
Co-authored papers 2
Co-authored papers 2
Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School
Co-authored papers 2
Dana-Farber Cancer Institute
Co-authored papers 2
Universite Paris Cite, INSERM, CNRS
Co-authored papers 2
Department of Pediatrics Boston Children's Hospital Boston Massachusetts USA.
Co-authored papers 1
Broad Institute of MIT and Harvard
Co-authored papers 1
INSERM UMR , St Louis Hospital, University of Paris
Co-authored papers 1
Lewis Sigler Institute for Integrative Genomics, Princeton University
Co-authored papers 1
Broad Institute of MIT and Harvard
Co-authored papers 1
Universite Paris Cite, INSERM, CNRS
Co-authored papers 1